|
1
|
Tan AC, Ashley DM, López GY, Malinzak M,
Friedman HS and Khasraw M: Management of glioblastoma: State of the
art and future directions. CA Cancer J Clin. 70:299–312.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sousa N, Geiß C, Bindila L, Lieberwirth I,
Kim E and Régnier-Vigouroux A: Targeting sphingolipid metabolism
with the sphingosine kinase inhibitor SKI-II overcomes
hypoxia-induced chemotherapy resistance in glioblastoma cells:
Effects on cell death, self-renewal, and invasion. BMC Cancer.
23(762)2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Thakur A, Faujdar C, Sharma R, Sharma S,
Malik B, Nepali K and Liou JP: Glioblastoma: Current status,
emerging targets, and recent advances. J Med Chem. 65:8596–8685.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Monteiro AR, Hill R, Pilkington GJ and
Madureira PA: The role of hypoxia in glioblastoma invasion. Cells.
6(45)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Walsh JC, Lebedev A, Aten E, Madsen K,
Marciano L and Kolb HC: The clinical importance of assessing tumor
hypoxia: Relationship of tumor hypoxia to prognosis and therapeutic
opportunities. Antioxid Redox Signal. 21:1516–1554. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ge X, Pan MH, Wang L, Li W, Jiang C, He J,
Abouzid K, Liu LZ, Shi Z and Jiang BH: Hypoxia-mediated
mitochondria apoptosis inhibition induces temozolomide treatment
resistance through miR-26a/Bad/Bax axis. Cell Death Dis.
9(1128)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Singh N, Miner A, Hennis L and Mittal S:
Mechanisms of temozolomide resistance in glioblastoma-a
comprehensive review. Cancer Drug Resist. 4:17–43. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mao XG, Xue XY, Lv R, Ji A, Shi TY, Chen
XY, Jiang XF and Zhang X: CEBPD is a master transcriptional factor
for hypoxia regulated proteins in glioblastoma and augments hypoxia
induced invasion through extracellular matrix-integrin mediated
EGFR/PI3K pathway. Cell Death Dis. 14(269)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chandel NS, McClintock DS, Feliciano CE,
Wood TM, Melendez JA, Rodriguez AM and Schumacker PT: Reactive
oxygen species generated at mitochondrial complex III stabilize
hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2
sensing. J Biol Chem. 275:25130–25138. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Schroedl C, McClintock DS, Budinger GRS
and Chandel NS: Hypoxic but not anoxic stabilization of HIF-1alpha
requires mitochondrial reactive oxygen species. Am J Physiol Lung
Cell Mol Physiol. 283:L922–L931. 2002.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Guzy RD, Hoyos B, Robin E, Chen H, Liu L,
Mansfield KD, Simon MC, Hammerling U and Schumacker PT:
Mitochondrial complex III is required for hypoxia-induced ROS
production and cellular oxygen sensing. Cell Metab. 1:401–408.
2005.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Masson N, Willam C, Maxwell PH, Pugh CW
and Ratcliffe PJ: Independent function of two destruction domains
in hypoxia-inducible factor-alpha chains activated by prolyl
hydroxylation. EMBO J. 20:5197–5206. 2001.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chan DA, Sutphin PD, Yen SE and Giaccia
AJ: Coordinate regulation of the oxygen-dependent degradation
domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol.
25:6415–6426. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kobayashi A, Kang MI, Okawa H, Ohtsuji M,
Zenke Y, Chiba T, Igarashi K and Yamamoto M: Oxidative stress
sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to
regulate proteasomal degradation of Nrf2. Mol Cell Biol.
24:7130–7139. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bae T, Hallis SP and Kwak MK: Hypoxia,
oxidative stress, and the interplay of HIFs and NRF2 signaling in
cancer. Exp Mol Med. 56:501–514. 2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ji X, Wang H, Zhu J, Zhu L, Pan H, Li W,
Zhou Y, Cong Z, Yan F and Chen S: Knockdown of Nrf2 suppresses
glioblastoma angiogenesis by inhibiting hypoxia-induced activation
of HIF-1α. Int J Cancer. 135:574–584. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tang T, Jia Y, Liang H, Han Y, Cong Z,
Wang H and Ji X: Knockdown of Nrf2 radiosensitizes glioma cells by
inducing redox stress and apoptosis in hypoxia. Transl Cancer Res.
11:4105–4116. 2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang XJ, Sun Z, Villeneuve NF, Zhang S,
Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, et al: Nrf2
enhances resistance of cancer cells to chemotherapeutic drugs, the
dark side of Nrf2. Carcinogenesis. 29:1235–1243. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tan Z, Luo X, Xiao L, Tang M, Bode AM,
Dong Z and Cao Y: The role of PGC1α in cancer metabolism and its
therapeutic implications. Mol Cancer Ther. 15:774–782.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Luchkova A, Mata A and Cadenas S: Nrf2 as
a regulator of energy metabolism and mitochondrial function. FEBS
Lett. 598:2092–2105. 2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Ren D, Villeneuve NF, Jiang T, Wu T, Lau
A, Toppin HA and Zhang DD: Brusatol enhances the efficacy of
chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Proc Natl Acad Sci USA. 108:1433–1438. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Harder B, Tian W, La Clair JJ, Tan AC, Ooi
A, Chapman E and Zhang DD: Brusatol overcomes chemoresistance
through inhibition of protein translation. Mol Carcinog.
56:1493–1500. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Olayanju A, Copple IM, Bryan HK, Edge GT,
Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, et al:
Brusatol provokes a rapid and transient inhibition of Nrf2
signaling and sensitizes mammalian cells to chemical
toxicity-implications for therapeutic targeting of Nrf2. Free Radic
Biol Med. 78:202–212. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shankar A, Jain M, Lim MJ, Angara K, Zeng
P, Arbab SA, Iskander A, Ara R, Arbab AS and Achyut BR: Anti-VEGFR2
driven nuclear translocation of VEGFR2 and acquired malignant
hallmarks are mutation dependent in glioblastoma. J Cancer Sci
Ther. 8:172–178. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Suppramote O, Prasopporn S, Aroonpruksakul
S, Ponvilawan B, Makjaroen J, Suntiparpluacha M, Korphaisarn K,
Charngkaew K, Chanwat R, Pisitkun T, et al: The acquired
vulnerability caused by CDK4/6 inhibition promotes drug synergism
between oxaliplatin and palbociclib in cholangiocarcinoma. Front
Oncol. 12(877194)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lohakul J, Chaiprasongsuk A, Jeayeng S,
Saelim M, Muanjumpon P, Thanachaiphiwat S, Tripatara P, Soontrapa
K, Lumlerdkij N, Akarasereenont P and Panich U: The protective
effect of polyherbal formulation, harak formula, on UVA-induced
photoaging of human dermal fibroblasts and mouse skin via promoting
Nrf2-regulated antioxidant defense. Front Pharmacol.
12(649820)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chaiprasongsuk A, Onkoksoong T,
Pluemsamran T, Limsaengurai S and Panich U: Photoprotection by
dietary phenolics against melanogenesis induced by UVA through
Nrf2-dependent antioxidant responses. Redox Biol. 8:79–90.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Htut NW, Onkoksoong T, Saelim M,
Kueanjinda P, Sampattavanich S and Panich U: Live-cell imaging
Unveils stimulus-specific dynamics of Nrf2 activation in UV-exposed
melanoma cells: Implications for antioxidant compound screening.
Free Radic Biol Med. 211:1–11. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Arfin S, Jha NK, Jha SK, Kesari KK,
Ruokolainen J, Roychoudhury S, Rathi B and Kumar D: Oxidative
stress in cancer cell metabolism. Antioxidants (Basel).
10(642)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Dai Z, Cai L, Chen Y, Wang S, Zhang Q,
Wang C, Tu M, Zhu Z, Li Q and Lu X: Brusatol inhibits proliferation
and invasion of glioblastoma by down-regulating the expression of
ECM1. Front Pharmacol. 12(775680)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gao Y, Zhang E, Liu B, Zhou K, He S, Feng
L, Wu G, Cao M, Wu H, Cui Y, et al: Integrated analysis identified
core signal pathways and hypoxic characteristics of human
glioblastoma. J Cell Mol Med. 23:6228–6237. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Culver C, Sundqvist A, Mudie S, Melvin A,
Xirodimas D and Rocha S: Mechanism of hypoxia-induced NF-kappaB.
Mol Cell Biol. 30:4901–4921. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Wang P, Zhao L, Gong S, Xiong S, Wang J,
Zou D, Pan J, Deng Y, Yan Q, Wu N and Liao B: HIF1α/HIF2α-Sox2/Klf4
promotes the malignant progression of glioblastoma via the
EGFR-PI3K/AKT signalling pathway with positive feedback under
hypoxia. Cell Death Dis. 12(312)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Luo Z, Tian M, Yang G, Tan Q, Chen Y, Li
G, Zhang Q, Li Y, Wan P and Wu J: Hypoxia signaling in human health
and diseases: Implications and prospects for therapeutics. Signal
Transduc Target Ther. 7(218)2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Unwith S, Zhao H, Hennah L and Ma D: The
potential role of HIF on tumour progression and dissemination. Int
J Cancer. 136:2491–2503. 2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lv X, Li J, Zhang C, Hu T, Li S, He S, Yan
H, Tan Y, Lei M, Wen M and Zuo J: The role of hypoxia-inducible
factors in tumor angiogenesis and cell metabolism. Genes Dis.
4:19–24. 2016.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Awuah WA, Toufik A-R, Yarlagadda R,
Mikhailova T, Mehta A, Huang H, Kundu M, Lopes L, Benson S, Mykola
L, et al: Exploring the role of Nrf2 signaling in glioblastoma
multiforme. Discov Oncol. 13(94)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Adinolfi S, Patinen T, Jawahar Deen A,
Pitkänen S, Härkönen J, Kansanen E, Küblbeck J and Levonen AL: The
KEAP1-NRF2 pathway: Targets for therapy and role in cancer. Redox
Biol. 63(102726)2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zhang J, Xu HX, Zhu JQ, Dou YX, Xian YF
and Lin ZX: Natural Nrf2 inhibitors: A review of their potential
for cancer treatment. Int J Biol Sci. 19:3029–3041. 2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Harifi-Mood MS, Alemzadeh E, Barati D,
Dehghani AH, Siroosi FZ, Aschner M, Samini F, Samarghandian S and
Farkhondeh T: The role of Nrf2 in glioma: Therapeutic targeting
strategies. Curr Cancer Drug Targets: February 14, 2025 (Epub ahead
of print).
|
|
42
|
Syu JP, Chi JT and Kung HN: Nrf2 is the
key to chemotherapy resistance in MCF7 breast cancer cells under
hypoxia. Oncotarget. 7:14659–14672. 2016.PubMed/NCBI View Article : Google Scholar
|
|
43
|
He T, Zhou F, Su A, Zhang Y, Xing Z, Mi L,
Li Z and Wu W: Brusatol: A potential sensitizing agent for cancer
therapy from Brucea javanica. Biomed Pharmacother.
158(114134)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Kolamunne RT, Dias IHK, Vernallis AB,
Grant MM and Griffiths HR: Nrf2 activation supports cell survival
during hypoxia and hypoxia/reoxygenation in cardiomyoblasts; the
roles of reactive oxygen and nitrogen species. Redox Biol.
1:418–426. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lu Y, Wang B, Shi Q, Wang X, Wang D and
Zhu L: Brusatol inhibits HIF-1 signaling pathway and suppresses
glucose uptake under hypoxic conditions in HCT116 cells. Sci Rep.
6(39123)2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Shostak K and Chariot A: EGFR and NF-κB:
Partners in cancer. Trends Mol Med. 21:385–393. 2015.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zhang M, Zhang YY, Chen Y, Wang J, Wang Q
and Lu H: TGF-β signaling and resistance to cancer therapy. Front
Cell Dev Biol. 9(786728)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Uribe ML, Marrocco I and Yarden Y: EGFR in
cancer: Signaling mechanisms, drugs, and acquired resistance.
Cancers (Basel). 13(2748)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Gong L, Yin Y, Chen C, Wan Q, Xia D, Wang
M, Pu Z, Zhang B and Zou J: Characterization of EGFR-reprogrammable
temozolomide-resistant cells in a model of glioblastoma. Cell Death
Discov. 8(438)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Lee SLO, Ryu H, Son AR, Seo B, Kim J, Jung
SY, Song JY, Hwang SG and Ahn J: TGF-β and hypoxia/reoxygenation
promote radioresistance of A549 lung cancer cells through
activation of Nrf2 and EGFR. Oxid Med Cell Longev.
2016(6823471)2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Lim SW, Chen WC, Ko HJ, Su YF, Wu CH,
Huang FL, Li CF and Tsai CY: 6-Gingerol induced apoptosis and cell
cycle arrest in glioma cells via MnSOD and ERK phosphorylation
modulation. Biomol Ther (Seoul). 33:129–142. 2025.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Lyons A, Coleman M, Riis S, Favre C,
O'Flanagan CH, Zhdanov AV, Papkovsky DB, Hursting SD and O'Connor
R: Insulin-like growth factor 1 signaling is essential for
mitochondrial biogenesis and mitophagy in cancer cells. J Biol
Chem. 292:16983–16998. 2017.PubMed/NCBI View Article : Google Scholar
|
